On-Q-ity, a Waltham, MA-based life sciences company focused on novel circulating tumor cell (CTC) capture and characterization for clinical researchers and physicians, has secured $5m in financing.
Backers include existing investors Mohr Davidow Ventures, Atlas Ventures, and Physic Ventures.
Led by new President and Chief Executive Officer Michael T. Stocum, MS, On-Q-ity is developing products and services for clinical researchers and physicians that will enhance decision-making across multiple cancer types.
Michael T. Stocum will lead the company in research and development, clinical collaborations and business opportunities.
Walt P. Carney, Ph.D., Chief Scientific Officer, will become Scientific Advisor.